Doxorubicin Plus Sorafenib in Treatment of Advanced Hepatocellular Carcinoma Reply

被引：3
|
作者：
Abou-Alfa, Ghassan [1 ]
Capanu, Marinela [2 ]
Saltz, Leonard [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2011年 / 305卷 / 08期
关键词：
PHASE-III;
D O I：
10.1001/jama.2011.160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：781 / 781
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma
    Nicolas Williet
    Olivier Dubreuil
    Tarek Boussaha
    Isabelle Trouilloud
    Bruno Landi
    Martin Housset
    Muriel Botti
    Philippe Rougier
    Jacques Belghiti
    Julien Taieb
    World Journal of Gastroenterology, 2011, 17 (17) : 2255 - 2258
  • [32] PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
    Abou-Alfa, Ghassan K.
    Chan, Stephan L.
    Lin, Chia-Chi
    Chiorean, E. Gabriela
    Holcombe, Randall F.
    Mulcahy, Mary F.
    Carter, William D.
    Patel, Kashyap
    Wilson, William R.
    Melink, Teresa J.
    Gutheil, John C.
    Tsao, Chao-Jung
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (02) : 539 - 545
  • [33] Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
    El Dika, Imane
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Ly, Michele
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Millang, Brittanie
    Ma, Jennifer
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    CANCER MEDICINE, 2020, 9 (20): : 7453 - 7459
  • [34] Sorafenib plus cisplatin for hepatocellular carcinoma
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (10): : E424 - E424
  • [35] Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma
    Abou Alfa, G. K.
    Johnson, P.
    Knox, J.
    Lacava, J.
    Leung, T.
    Mori, A.
    Leberre, M. A.
    Voliotis, D.
    Saltz, L.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 259
  • [36] Phase II trial of sorafenib plus doxorubicin (SD) in patients (Pts) with advanced hepatocellular carcinoma (HCC) after progression of disease (PD) on sorafenib (S).
    El Dika, Imane H.
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Germino, Joseph
    O'Reilly, Eileen Mary
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [37] A case of rhabdomyolysis related to sorafenib treatment for advanced hepatocellular carcinoma
    Tsuji K.
    Takemura K.
    Minami K.
    Teramoto R.
    Nakashima K.
    Yamada S.
    Doyama H.
    Oiwake H.
    Hasatani K.
    Clinical Journal of Gastroenterology, 2013, 6 (3) : 255 - 257
  • [38] Sorafenib for the treatment of patients with advanced hepatocellular carcinoma and alcoholic cirrhosis
    Giovanis, P.
    Vincenzi, V.
    Manuppelli, C.
    Berletti, R.
    Marcante, M.
    Ricagna, F.
    Pinto, F.
    Giusto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [39] Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review
    Zhang, Xin
    Yang, Xin-Rong
    Huang, Xiao-Wu
    Wang, Wei-Min
    Shi, Ruo-Yu
    Xu, Yang
    Wang, Zheng
    Qiu, Shuang-Jian
    Fan, Jia
    Zhou, Jian
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2012, 11 (05) : 458 - 466
  • [40] SORAFENIB FOR THE TREATMENT OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND ALCOHOLIC CIRRHOSIS
    Giovanis, P.
    Vincenzi, V.
    Manuppelli, C.
    Berletti, R.
    Ricagna, F.
    Giusto, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S246 - S247
12345